copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Johnson Johnson reports Q2 2025 results; raises 2025 outlook New Brunswick, N J (July 16, 2025) – Johnson Johnson (NYSE: JNJ) today announced results for second-quarter 2025 “Today’s strong results reflect the depth and strength of Johnson Johnson ’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson “Our portfolio and
Johnson Johnson: Changing health for humanity Johnson Johnson MedTech innovates at the intersection of biology and technology With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex diseases Healthcare areas include: Cardiovascular, Orthopaedics, Surgery and
Media Center - Johnson Johnson Read the latest press releases from Johnson Johnson, find our press contacts and see our latest social media posts
Contact us - Johnson Johnson Get in touch with Johnson JohnsonDo not sell or share my personal information Limit the use of my sensitive personal information
Global Johnson Johnson websites If you don’t see your country or region represented above, please click below to find links to the company’s Innovative Medicine and MedTech country and regional websites
Investor Relations | Johnson Johnson The J J value At Johnson Johnson, we believe health is everything Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal About Johnson Johnson
Johnson Johnson Reports Q4 and Full-Year 2024 Results NEW BRUNSWICK, N J -- (BUSINESS WIRE)-- Johnson Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024 "2024 was a transformative year for Johnson Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson “As a healthcare company
Johnson Johnson to break ground on new state-of-the-art biologics . . . Johnson Johnson to break ground on new state-of-the-art biologics facility in North Carolina to deliver market-leading portfolio of transformational therapies • New facility will support plans to advance J J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases • Delivering on Company’s plans for increased U S investment, $2
News and insights - Johnson Johnson A collection of stories that highlight the way Johnson Johnson is making an impact in the lives of its consumers, and the latest press releases from the company